Influence of Association Type of Bisphosphonates with Calcium-deficient Apatite on Drug Release

摘要

Bisphosphonates (BP) are one of the most potent inhibitors of bone resorption by preventing osteoclast activity. Thus, they constitute a class of drug that are increasingly used to treat bone diseases characterized by enhanced osteoclastic bone resorption and are prescribed for the treatment of patients suffering from osteoporosis, Paget's disease, or bone cancers (1, 2). For these treatments, bisphosphonates are administrated either by intravenous route every 3-4 weeks, or once daily by oral route. These two modes of administration are not convenient for the patients. Indeed, parenteral administration requires a patient monitoring for several hours and oral route often suffers from low bioavailability and shows gastrointestinal disturbances, which can induce poor compliance (3).